Skip to main content
SpringerLink
Log in

Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)

  • Chapter
  • First Online:
Management of Castration Resistant Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 873 Accesses

Abstract

Since 2004 docetaxel has been standard first-line chemotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel improves survival and provides superior palliative benefit as demonstrated in the TAX327 and the Southwest Oncology Group 99-16 studies. None of the eight subsequent phase III docetaxel-based combination trials have demonstrated to further improve survival by adding a second drug. For patients who progress after docetaxel chemotherapy, several new treatment options have recently become available. The taxane cabazitaxel has shown survival benefit in patients who progressed during or after treatment with docetaxel. With new therapies like abiraterone and enzalutamide becoming available also pre-chemotherapy, the challenge has become to determine the optimal treatment sequence and best treatment choice for an individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.

    CAS  PubMed  Google Scholar 

  2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506–13.

    CAS  PubMed  Google Scholar 

  3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277: 665–7.

    Article  CAS  PubMed  Google Scholar 

  4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Vrignaud P, Semiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013; 19:2973–83.

    Article  CAS  PubMed  Google Scholar 

  6. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992–8002.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49:3821–30.

    Google Scholar 

  9. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273–9.

    Article  CAS  PubMed  Google Scholar 

  10. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14–8.

    CAS  PubMed  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  CAS  PubMed  Google Scholar 

  12. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  CAS  PubMed  Google Scholar 

  13. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–5.

    Article  CAS  PubMed  Google Scholar 

  14. Meulenbeld HJ, Hamberg P, de Wit R. Chemotherapy in patients with castration-resistant prostate cancer. Eur J Cancer. 2009;45 Suppl 1:161–71.

    Article  PubMed  Google Scholar 

  15. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396–403.

    Article  CAS  PubMed  Google Scholar 

  16. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14:2763–7.

    Article  CAS  PubMed  Google Scholar 

  17. Azria D, Massard C, Tosi D, Houede N, Joly F, Gravis G. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. J Clin Oncol. 2012;30(suppl 5; abstr 149).

    Google Scholar 

  18. Heidenreich A, Pfister D. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol. 2012; 62:1201–4.

    Article  PubMed  Google Scholar 

  19. Loriot Y, Massard C, Albiges L, Di Palma M, Blanchard P, Bossi A, et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol. 2012;30(suppl 5; abstr 213).

    Google Scholar 

  20. van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, De Wit R. The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: data from the TAX 327 study. Eur Urol. 2013; S0302-2838(13):00828–2 (Epub ahead of print).

    Google Scholar 

  21. Huillard O, Albiges L, Eymard JC, Massard C, Di Palma M, Escudier BJ, et al. Efficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR). J Clin Oncol. 2013;31(suppl; abstr 5075).

    Google Scholar 

  22. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943–7.

    Article  CAS  PubMed  Google Scholar 

  23. Pezaro C, Le Moulec S, Albiges L, Omlin A, Loriot Y, Bianchini D, et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. J Clin Oncol. 2013;31(suppl 6; abstr 186).

    Google Scholar 

  24. Oudard S, Maillet D, Fléchon A, Ozguroglu M, Mercier F, Guillot A. Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(suppl 6; abstr 137).

    Google Scholar 

  25. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011;107:234–9.

    Article  PubMed  Google Scholar 

  26. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 2011;107 Suppl 2:13–20.

    Article  CAS  PubMed  Google Scholar 

  27. Pfister DJ, Porres D, Piper C, Merseburger AS, Klotz T, Heidenreich A. Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy. J Clin Oncol. 2012;30(suppl 5; abstr 243).

    Google Scholar 

  28. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995–2005.

    Article  PubMed Central  PubMed  Google Scholar 

  29. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    Article  PubMed  Google Scholar 

  30. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  31. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112:326–30.

    Article  CAS  PubMed  Google Scholar 

  32. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007;61:243–54.

    Article  PubMed  Google Scholar 

  33. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med. 2011;364:2055–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: 2009 genitourinary cancers symposium.

    Google Scholar 

  35. Higano C, Saad F, Somer B, Curti B, Petrylak D, Drake CG, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). In: 2009 genitourinary cancers symposium.

    Google Scholar 

  36. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol. 2001;28: 49–55.

    Article  CAS  PubMed  Google Scholar 

  37. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25- dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7:1043–51.

    CAS  PubMed  Google Scholar 

  38. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669–74.

    Article  CAS  PubMed  Google Scholar 

  39. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29:2191–8.

    Article  CAS  PubMed  Google Scholar 

  40. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia. 2006;8:725–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007;67:3818–26.

    Article  CAS  PubMed  Google Scholar 

  42. Quinn DI, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol. 2012;30 (suppl; abstr 4511).

    Google Scholar 

  43. Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31: 1740–7.

    Article  CAS  PubMed  Google Scholar 

  44. Retter AS, Figg WD, Dahut WL. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer. 2003;2: 153–9.

    Article  CAS  PubMed  Google Scholar 

  45. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–9.

    Article  CAS  PubMed  Google Scholar 

  46. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888–93.

    CAS  PubMed  Google Scholar 

  47. Petrylak DP, Fizazi K, Sternberg CN, et al: A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial. 2012 ESMO Congress. Abstract LBA24. Presented September 30, 2012.

    Google Scholar 

  48. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 (Epub ahead of print).

    Google Scholar 

  50. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323–33.

    Article  CAS  PubMed  Google Scholar 

  51. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer. 2003;39:1927–35.

    Article  CAS  PubMed  Google Scholar 

  52. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem. 2004;279:17660–6.

    Article  CAS  PubMed  Google Scholar 

  53. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17: 5546–52.

    Article  CAS  PubMed  Google Scholar 

  54. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1–2 study. Cancer. 2012; 118:63–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Araujo JC, Trudel GC, Saad F. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol. 2013 (suppl 6; abstr LBA8).

    Google Scholar 

  56. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010;16:1088–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–97.

    Article  CAS  PubMed  Google Scholar 

  58. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:4247–54.

    Article  CAS  PubMed  Google Scholar 

  59. Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012; 23:1803–8.

    Article  CAS  PubMed  Google Scholar 

  60. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:1264–9.

    Article  CAS  PubMed  Google Scholar 

  61. Horti J, Widmark A, Stenzl A, Federico MH, Abratt RP, Sanders N, et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm. 2009;24:175–80.

    Article  CAS  PubMed  Google Scholar 

  62. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012; 23:688–94.

    Article  CAS  PubMed  Google Scholar 

  63. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, et al. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2009;27 (suppl; abstr e16055).

    Google Scholar 

  64. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007;13:5816–24.

    Article  CAS  PubMed  Google Scholar 

  65. Antonarakis ES, Eisenberger MA. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol. 2013;31:1709–12.

    Article  CAS  PubMed  Google Scholar 

  66. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–30.

    Article  CAS  PubMed  Google Scholar 

  67. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547–52.

    Article  CAS  PubMed  Google Scholar 

  68. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats. Br J Pharmacol. 2003;138:1367–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037–45.

    Article  CAS  PubMed  Google Scholar 

  70. Oudard S, de Bono JS, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Impact of cabazitaxel + prednisone on overall survival at 2 years and in patients with aggressive disease: post-hoc analyses of TROPIC trial. Ann Oncol. 2012;23(suppl 9; abstr 933).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Robert J. van Soest MD & Ellen S. de Morrée MSc

  2. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

    Cora N. Sternberg MD, FACP

  3. Department of Medical Oncology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, Rotterdam, 3075 EA, The Netherlands

    Ronald de Wit MD, PhD

Authors
  1. Robert J. van Soest MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen S. de Morrée MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cora N. Sternberg MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald de Wit MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald de Wit MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Montreal Hospital Center, Montreal, Québec, Canada

    Fred Saad

  2. Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA

    Mario A. Eisenberger

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

van Soest, R.J., de Morrée, E.S., Sternberg, C.N., de Wit, R. (2014). Cytotoxic Chemotherapy (Taxanes and Taxane Combinations). In: Saad, F., Eisenberger, M. (eds) Management of Castration Resistant Prostate Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1176-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1176-9_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1175-2

  • Online ISBN: 978-1-4939-1176-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation